This was confirmed by several previous studies in ovarian cancer tissues, which showed that patients who had tumours with high nuclear expression of pStat3 had poorer survival rates and shorter survival than women who had tumours with low nuclear pStat3 expression.8, 9 These results suggest that targeting Stat3 presents a feasible strategy to improve the outcomes of patients with ovarian cancer. Here, STAT3 is linked to ovarian carcinoma.